This bill matters because it directly impacts the cost of certain prescription drugs for Americans, especially those covered by Medicare. If it becomes law, drug manufacturers would have a longer window to sell drugs for rare diseases without government-mandated price reductions. This could motivate companies to develop more treatments for conditions that currently lack them, potentially offering hope to patients with rare diseases.

However, this also means that taxpayers and Medicare beneficiaries might pay higher prices for these drugs for a longer duration than under current law. Without this bill, drugs for rare diseases might become eligible for price negotiation sooner, potentially leading to lower costs for the government and patients. The debate centers on balancing incentives for pharmaceutical innovation with efforts to control drug spending.